Sulfacetamide loaded eudragit RL100 nanosuspension with potential for ocular delivery

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 4, 2010, Pages 510-523

  Mandal, Bivash ^a   Alexander, Kenneth S ^a   Riga, Alan T ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EUDRAGIT; MANNITOL; POLY(METHYL METHACRYLATE); SUCROSE; SULFACETAMIDE;

ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; FREEZE DRYING; INFRARED SPECTROSCOPY; NANOSUSPENSION; PARTICLE SIZE; PH; SURFACE CHARGE; SUSPENSION; SUSTAINED DRUG RELEASE; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

EID: 78650339231     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3sw2t     Document Type: Article

References (51)

1. Jennifer JKD, William FM. Thermoresponsive hydrogels as a new ocular drug delivery platform to the poterior segment of eye. Trans Am Ophthalmol Soc, 2008;106:206-214.
2. Joshi A. Microparticulates for Ophthalmic Drug Delivery. J Ocul Pharmacol,1994;10(1):29-45.
3. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Release, 2009;136(1):2-13.
4. Nagarsenker MS, Londhe VY and Nadkarni GD. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm, 1999;190(1):63-71.
5. Yoel G, Guy K. Use of collagen shields for ocularsurface drug delivery. Expert Rev Ophthalmol, 2008;3(6): 627-633.
6. Bloomfield SE, Miyata T, Dunn MW, Bueser N, Stenzel KH, Rubin AL. Soluble Gentamicin Ophthalmic Inserts as a Drug Delivery System. Arch Ophthalmol, 1978; 96(5):885-887.
7. Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release, 2005; 102(1): 23-38.
8. Monti D, Saccomani L, Chetoni P, Burgalassi S, Saettone MF. Effect of iontophoresis on transcorneal permeation 'in vitro' of two β-blocking agents and on corneal hydration. Int J Pharm, 2003; 250(2):423-429.
9. Antoine BR, Francine BC, David B, Robert G, Florence D. Polymeric nanoparticles for drug delivery to the posterior segment of the eye. CHIMIA Intl J Chem, 2005;59(6):344-347.
10. Kreuter J, Nanoparticles in Kreuter J(ed), Colloidal Drug Delivery Systems, Marcel Dekker, INC, New York, NY, pp 219-342, 1994
11. Roth HW, Leimbeck R, Sonnenschein B, Anger CB, Weber S. The effective antibacterial spectrum of sulfacetamide. Klin Monbl Augenheilkd, 1992;200(3):182-186.
12. Abboud I, Massoud WH. Effect of blephamide in blepharitis. Bull Ophthalmol Soc Egypt, 1972;65(69):539-543.
13. Chhibber PR. Treatment of trachoma. Ind J Med Res, 1964;58:3-8.
14. Colomina J, Esparza L, Buesa J, Marí J. Corneal ulcer caused by Nocardia asteroides after penetrating keratoplasty. Med Clin (Barc), 1997; 108(11):424-425.
15. Sridhar MS, Sharma S, Reddy MK, Mruthyunjay P, Rao GN. Clinicomicrobiological review of Nocardia keratitis. Cornea,1998;17(1):17-22.
16. Brown GM. Inhibition by sulfonamides of the biosynthesis of folic acid. Int J Lepr Other Mycobact Dis, 1967;35(4):580-589.
17. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 12th ed, Laxi-Comp inc: Hudson: Ohio; 2004.
18. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci, 2002;16(1-2):53-61.
19. Castelli F, Messina C, Sarpietro MG, Pignatello R, Puglisi G. Flurbiprofen Release From Eudragit RS and RL Aqueous Nanosuspensions: a Kinetic Study by DSC and Dialysis Experiments. AAPS Pharm Sci Tech, 2002;3(2):article 9.
20. Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation and Characterization of Eudragit Retard Nanosuspensions for the Ocular Delivery of Cloricromene. AAPS PharmSciTech, 2006;7(1):Article 27.
21. Adibkia K, Siahi MR, Nokhodchi A, Javadzedeh AR, Barzegar-Jalali M, Barar J, Mohammadi G, Omidi Y. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target, 2007;15(6):407-16.
22. Adibkia K, Omidi Y, Siahi MR, Javadzedeh AR, Barzegar-Jalali M, Barar J, Maleki N, Mohammadi G, Nokhodchi A. Inhibition of Endotoxin-Induced Uveitis by Methylprednisolone Acetate Nanosuspension in Rabbits. J Ocul Pharmacol Ther, 2007; 23(5): 421-432.
23. Das S, Sureshb PK, Desmukhc R. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine: Nanotechnology, Biology and Medicine, 2010; 6 (2): 318-323.
24. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm, 1989; 55(1):r1-r4.
25. Hornig S, Heinze T, Becer CR, Schubert US. Synthetic polymeric nanoparticles by nanoprecipitation. J Mater Chem,2009;19:3838-3840.
26. Peltonen L, Aitta J, Hyvönen S, Karjalainen M, Hirvonen J. Improved Entrapment Efficiency of Hydrophilic Drug Substance During Nanoprecipitation of Poly(l)lactide Nanoparticles. AAPS PharmSciTech, 2004; 5(1):article 16.
27. Sensoy D, Cevher E, Sarici A, Yilmaz M., Özdamar A, Bergişadi N. Bioadhesive sulfacetamide sodium microspheres: Evaluation of their effectiveness in the treatment of bacterial keratitis caused by Staphylococcus aureus and Pseudomonas aeruginosa in a rabbit model. Eur J Pharm Biopharm, 2009;72(3):487-495.
28. Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VH. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res, 2004;21(4):641-648.
29. Govender T, Stolnik S, Garnett MC, Illum L and Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release, 1999;57(2):171-185.
30. Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci, 1969;58(10):1253-1257.
31. Higuchi T. Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 1963;52:1145-1149.
32. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation: I-theoretical consideration. Ind Eng Chem Res, 1931; 23:923-931.
33. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppa s NA. Mechanisms of solute release from porous hydrophilic polymers.Int J Pharm, 1983;15:25-35.
34. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 2002;23(15):3247-3255.
35. Csóka G, Gelencsér A, Kiss D, Pásztor E, Klebovich I, Zelkó R. Comparison of the fragility index of different eudragit polymers determined by activation enthalpies. J Therm Anal Calorim, 2007; 87 (2): 2469-473.
36. Shivakumar HN, Desai BG, Deshmukh G. Design and Optimization of Diclofenac Sodium Controlled Release Solid Dispersions by Response Surface Methodology. Indian J Pharm Sci, 2008; 70(1): 22-30.
37. Boutonnet-Fagegaltier N, Menegotto J, Lamure A, Duplaa H, Caron A, Lacabanne C, Bauer M. Molecular mobility study of amorphous and crystalline phases of a pharmaceutical product by thermally stimulated current spectrometry. J Pharm Sci, 2002; 91: 1548-1560.
38. Boyer RF. Transitions and relaxations in amorphous and semicrystalline organic polymers and copolymers. In: Encyclopedia of Polymer Science and Technology; Vol II 1977, New York: John Wiley & Sons, Inc.; pp. 745-839.
39. Nagendrappa G. An elegant example of chemoselective reaction. Resonance, 2008; 13(10), 929-940.
40. Basu SK, Adhiyaman R. Preparation and Characterization of Nitrendipine loaded Eudragit RL 100 Microspheres Prepared by an Emulsion-Solvent Evaporation Method. Tropical J Pharm Res, 2008; 7 (3): 1033-1041.
41. Pignatello R, Consoli P, Puglisi G. In vitro release kinetics of Tolmetin from tabletted Eudragit microparticles. J Microencapsul, 2000;17(3):373-383.
42. Marangoni C. Über die Ausbreitung der Tropfeneiner Flüssigkeit auf der Oberflächeeineranderen. Annalen der Physik und Chemie,1871; 219:337-354.
43. Mecklenburg W. The relation between the Tyndall effect and the size of the particles of colloidal solutions. Kolloid-Zeitschrift, 1915;16:97-103.
44. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Del Rev, 1995;16(1):61-73.
45. Marchal-Heussler L, Maincent P, Hoffman M, Spittler J, Couvreur P. Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutylcyanoacrylate nanoparticle preparations. Int J Pharm, 1990;58(2):115-122.
46. Ter VR, Fromell K, Caldwell KD. Shifts in polystyrene particle surface charge upon adsorption of the Pluronic F108 surfactant. J Colloid Interface Sci, 2005;288(1):124-128.
47. Hou Z, Wei H, Wang Q, Sun Q, Zhou C, Zhan C, Tang X, Zhang Q. New Method to Prepare Mitomycin C Loaded PLA-Nanoparticles with High Drug Entrapment Efficiency. Nanoscale Res Lett, 2009; 4(7): 732-737.
48. Xu X, Fu Y, Hu H, Duan Y, Zhang Z. Quantitative determination of insulin entrapment efficiency in triblock copolymeric nanoparticles by highperformance liquid chromatography. J Pharm Biomed Anal, 2006;41(1):266-273.
49. Quinteros DA, Rigo VR, Kairuz AF, Olivera ME, Manzo RH, AllemandiDA. Interaction between a cationic polymethacrylate (Eudragit E100) and anionic drugs. Eur J Pharm Sci, 2008; 33(1):72-9.
50. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci, 2002;6(4):319-327.
51. KIlIÇarslan M, Baykara T. Effects of the permeability characteristics of different polymethacrylates on the pharmaceutical characteristics of verapamil hydrochloride-loaded microspheres. Journal of Microencapsulation 2004, 21(2), 175-189.